uniQure (NASDAQ:QURE) Director Sells $73,765.56 in Stock

uniQure N.V. (NASDAQ:QURE) Director Robert Gut sold 2,726 shares of uniQure stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $27.06, for a total transaction of $73,765.56. Following the completion of the sale, the director owned 32,259 shares in the company, valued at approximately $872,928.54. This represents a 7.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Robert Gut also recently made the following trade(s):

• On Wednesday, June 10th, Robert Gut sold 7,552 shares of uniQure stock. The shares were sold at an average price of $26.05, for a total transaction of $196,729.60.

uniQure Stock Performance

NASDAQ:QURE traded up $0.75 during mid-day trading on Friday, hitting $27.57. The stock had a trading volume of 835,627 shares, compared to its average volume of 2,601,234. uniQure N.V. has a 52 week low of $8.73 and a 52 week high of $71.50. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of -7.92 and a beta of 0.98. The company has a 50 day simple moving average of $22.31 and a 200-day simple moving average of $21.76. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The company had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. On average, research analysts expect that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on QURE. Stifel Nicolaus set a $28.00 price target on shares of uniQure in a research report on Tuesday, May 5th. Wolfe Research began coverage on shares of uniQure in a research report on Monday, February 23rd. They set a “peer perform” rating on the stock. Wells Fargo & Company upgraded shares of uniQure from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $15.00 to $60.00 in a research report on Monday, March 9th. TD Cowen restated a “buy” rating on shares of uniQure in a research report on Tuesday, March 3rd. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $9.00 price objective (down from $55.00) on shares of uniQure in a research note on Monday, March 2nd. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $42.83.

Hedge Funds Weigh In On uniQure

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of uniQure by 15.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock valued at $65,673,000 after acquiring an additional 152,417 shares in the last quarter. Aberdeen Group plc lifted its position in shares of uniQure by 6.9% in the 3rd quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock valued at $171,593,000 after acquiring an additional 189,029 shares in the last quarter. Quinn Opportunity Partners LLC purchased a new stake in shares of uniQure in the 3rd quarter valued at approximately $6,281,000. Farallon Capital Management LLC lifted its position in shares of uniQure by 3,935.7% in the 3rd quarter. Farallon Capital Management LLC now owns 565,000 shares of the biotechnology company’s stock valued at $32,979,000 after acquiring an additional 551,000 shares in the last quarter. Finally, Boone Capital Management LLC purchased a new stake in shares of uniQure in the 3rd quarter valued at approximately $8,599,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.